Limited Coverage Drugs - Umeclidinium
Umeclidinium 62.5 mcg
|Form||dry powder for oral inhalation via inhaler|
|Special Authority Criteria||Approval Period|
Diagnosis of Chronic Obstructive Pulmonary Disease (COPD), where spirometry measures are:
- Practitioners in the following specialty are not required to submit a Special Authority request form for coverage: Respirology.
- In remote areas, where spirometry access is limited, spirometry measurements are to be provided within 6 months.
- Patients who meet the Special Authority criteria for aclidinium/glycopyrronium/tiotropium will automatically receive coverage of umeclidinium.